91-LB: Glycemic and Metabolic Effects of Long-Acting GLP-1 in T1D

Abstract

GLP-1 receptor agonists were studied as adjunct therapies in T1D. While short-acting GLP-1 agents are not approved for T1D due to concern of increased DKA risk, long-acting GLP-1 medications are commonly prescribed for T1D. Our study aims to evaluate glycemic and metabolic benefits of long-acting GLP-1 therapy in T1D and assess safety concerns. We conducted a retrospective chart review of T1D patients on a long-acting GLP-1 for at least six months. Parameters collected were A1c, 14-day CGM data at each visit, and metabolic data. Data from two years prior to starting GLP-1, and six or more months after starting GLP-1 were included. We identified 54 participants with T1D on a long-acting GLP-1 (Semaglutide, Dulaglutide, long acting Exenatide, Albiglutide) . Mean GLP-1 duration was 23.85 mo ± 15.46. We found a significant increase in time in range, and significant reductions in A1c, time in hyperglycemia, 14-day Blood Glucose SD, DKA hospitalization, and weight after starting a long-acting GLP-1. Time in hypoglycemia decreased non-significantly. Full data can be found in Table 1.As more data emerges on cardiovascular and renal benefits of long acting GLP-1 in type 2 Diabetes, there have been no reported outcomes in T1D. Our study is the first and the only one that demonstrates glycemic and metabolic benefits of this class in T1D, and safety of its use over 1.5-2 years. It represents real life experience. This data needs to be confirmed by prospective studies. Disclosure D. Mohandas: None. C. Gao: None. J. Calma: None. M. Basina: None.